Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma, Inc. (IMMX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, September 29, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis
How this was made
The 30-second read
Why it matters
The $125 M financing will fund clinical development and working capital, but the issuance of 11.3 M new shares may dilute existing shareholders.
Market read
First‑report 8‑K disclosure of a sizable equity raise; likely moves IMMX stock in the short term.
What to watch
Potential regulatory milestones for NXC‑201 could offset dilution concerns if data readouts are positive.
Background
Immix Biopharma (Nasdaq: IMMX) is a biotech focused on relapsed/refractory AL amyloidosis, developing the CAR‑T candidate NXC‑201.
Ticker impact
Immix Biopharma announced pricing of a $125 million underwritten common stock offering.
likely short‑term pressure as market prices dilution, with potential upside if trial data improves.
First‑report 8‑K disclosure of a sizable equity raise; investors typically react to dilution risk versus cash infusion.
Market effects
Adds funding to the biotech sector, may boost sentiment for AL amyloidosis therapeutics.
Limited to US biotech investors; no broader regional effect.
Modest; primarily impacts Immix and peers tracking CAR‑T developments.
Counterpoint
The raise could be seen as a sign of cash‑flow stress, suggesting a near‑term sell‑off.
Key entities
- financial_institutionJ.P. Morgan
Sole book‑running manager for the offering.
- productNXC‑201
Lead CAR‑T candidate targeting BCMA for AL amyloidosis.